Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Maha Hussain et al.|The Lancet Oncology|2021Cited by 411
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R. McKay, Toni K. Choueiri, Bradley A. McGregor et al.|Journal of Clinical Oncology|2020Cited by 105
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Toni K. Choueiri, Nieves Martínez Chanzá et al.|JAMA Oncology|2021Cited by 95
Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb studyYousef Zakharia, Mohammed Milhem|Oncotarget|2017Cited by 37
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I TrialEspen B. Ellingsen, Yousef Zakharia, Steven O’Day et al.|Clinical Cancer Research|2023Cited by 27